AroCell AB (AROC) - Total Assets
Based on the latest financial reports, AroCell AB (AROC) holds total assets worth Skr122.88 Million SEK (≈ $13.22 Million USD) as of March 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AROC debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
AroCell AB - Total Assets Trend (2007–2024)
This chart illustrates how AroCell AB's total assets have evolved over time, based on quarterly financial data. See what is AroCell AB's book value for net asset value and shareholders' equity analysis.
AroCell AB - Asset Composition Analysis
Current Asset Composition (December 2024)
AroCell AB's total assets of Skr122.88 Million consist of 49.9% current assets and 50.1% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 35.6% |
| Accounts Receivable | Skr12.33 Million | 9.2% |
| Inventory | Skr5.73 Million | 4.3% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr5.81 Million | 4.3% |
| Goodwill | Skr59.41 Million | 44.3% |
Asset Composition Trend (2007–2024)
This chart illustrates how AroCell AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AroCell AB market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AroCell AB's current assets represent 49.9% of total assets in 2024, an increase from 0.0% in 2007.
- Cash Position: Cash and equivalents constituted 35.6% of total assets in 2024, down from 66.7% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 8.0% in 2007.
- Asset Diversification: The largest asset category is goodwill at 44.3% of total assets.
AroCell AB Competitors by Total Assets
Key competitors of AroCell AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882
|
China | CN¥9.20 Billion |
|
Shanghai Labway Clinical Laboratory Co Ltd
SHE:301060
|
China | CN¥2.35 Billion |
|
Ningbo MedicalSystem Biotechnology Co Ltd
SHE:300439
|
China | CN¥3.66 Billion |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
|
INIFY LABORATORIES AB
F:WY60
|
Germany | €204.64 Million |
|
Check Cap Ltd
NASDAQ:CHEK
|
USA | $377.00K |
AroCell AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.69 | 5.78 | 13.79 |
| Quick Ratio | 4.24 | 5.16 | 13.36 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr51.68 Million | Skr54.56 Million | Skr50.09 Million |
AroCell AB - Advanced Valuation Insights
This section examines the relationship between AroCell AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.13 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | -23.3% |
| Total Assets | Skr134.13 Million |
| Market Capitalization | $13.39 Million USD |
Valuation Analysis
Below Book Valuation: The market values AroCell AB's assets below their book value (0.10x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: AroCell AB's assets decreased by 23.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for AroCell AB (2007–2024)
The table below shows the annual total assets of AroCell AB from 2007 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr134.13 Million ≈ $14.43 Million |
-23.31% |
| 2023-12-31 | Skr174.89 Million ≈ $18.82 Million |
-25.90% |
| 2022-12-31 | Skr236.01 Million ≈ $25.40 Million |
+3.78% |
| 2021-12-31 | Skr227.41 Million ≈ $24.47 Million |
+276.04% |
| 2020-12-31 | Skr60.48 Million ≈ $6.51 Million |
-33.81% |
| 2019-12-31 | Skr91.37 Million ≈ $9.83 Million |
+59.14% |
| 2018-12-31 | Skr57.42 Million ≈ $6.18 Million |
+15.96% |
| 2017-12-31 | Skr49.51 Million ≈ $5.33 Million |
-25.45% |
| 2016-12-31 | Skr66.42 Million ≈ $7.15 Million |
-10.63% |
| 2015-12-31 | Skr74.32 Million ≈ $8.00 Million |
+92.54% |
| 2014-12-31 | Skr38.60 Million ≈ $4.15 Million |
+113.92% |
| 2013-12-31 | Skr18.05 Million ≈ $1.94 Million |
+50.63% |
| 2012-12-31 | Skr11.98 Million ≈ $1.29 Million |
+70.76% |
| 2011-12-31 | Skr7.02 Million ≈ $754.98K |
+92.75% |
| 2010-12-31 | Skr3.64 Million ≈ $391.69K |
+51.03% |
| 2009-12-31 | Skr2.41 Million ≈ $259.35K |
+83.41% |
| 2008-12-31 | Skr1.31 Million ≈ $141.41K |
-21.88% |
| 2007-12-31 | Skr1.68 Million ≈ $181.01K |
-- |
About AroCell AB
AroCell AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cell; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. The company was formerly known as Xi Bao Research AB… Read more